
Flavio Kapczinski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1791445/publications.pdf Version: 2024-02-01



FLAVIO KADOZINSKI

#	Article	IF	CITATIONS
1	Bipolar disorder triggered by Covid-19 infection. Trends in Psychiatry and Psychotherapy, 2023, , .	0.8	Ο
2	Biomarkers of neuroprogression and late staging in bipolar disorder: A systematic review. Australian and New Zealand Journal of Psychiatry, 2023, 57, 328-343.	2.3	9
3	Data-driven cognitive phenotypes in subjects with bipolar disorder and their clinical markers of severity. Psychological Medicine, 2022, 52, 1728-1735.	4.5	7
4	Cognitive impairment in bipolar disorder in comparison to mild cognitive impairment and dementia: a systematic review. Trends in Psychiatry and Psychotherapy, 2022, , .	0.8	2
5	Prediction of suicide attempts in a prospective cohort study with a nationally representative sample of the US population. Psychological Medicine, 2022, 52, 2985-2996.	4.5	16
6	Precision Psychiatry: The Future Is Now. Canadian Journal of Psychiatry, 2022, 67, 21-25.	1.9	16
7	Lifestyle predictors of depression and anxiety during COVID-19: a machine learning approach. Trends in Psychiatry and Psychotherapy, 2022, , .	0.8	2
8	Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Cannabis and Cannabinoid Research, 2022, 7, 658-669.	2.9	22
9	What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines. Journal of Affective Disorders, 2022, 298, 565-576.	4.1	8
10	Functional and cognitive impairment in the first episode of depression: A systematic review. Acta Psychiatrica Scandinavica, 2022, 145, 156-185.	4.5	42
11	Physician suicide demographics and the COVID-19 pandemic. Revista Brasileira De Psiquiatria, 2022, 44, 124-135.	1.7	5
12	Network properties of intracortical myelin associated with psychosocial functioning in bipolar I disorder. Bipolar Disorders, 2022, , .	1.9	1
13	Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatmentâ€resistant depression. Human Psychopharmacology, 2022, 37, e2836.	1.5	13
14	Investigating biological rhythms disruptions across the menstrual cycle in women with comorbid bipolar disorder and premenstrual dysphoric disorder. Archives of Women's Mental Health, 2022, 25, 345-353.	2.6	2
15	Conversion to major neurocognitive disorder after COVIDâ€19 in a woman with bipolar disorder: A 6â€year longitudinal case report. Bipolar Disorders, 2022, 24, 451-456.	1.9	1
16	A qualitative study exploring the process of postmortem brain tissue donation after suicide. Scientific Reports, 2022, 12, 4710.	3.3	1
17	Suicide attempt, impulsivity, and exposure to trauma in college students. Revista Brasileira De Psiquiatria, 2022, , .	1.7	3
18	The impact of substance use disorder comorbidity on cognition of individuals with bipolar disorder: A systematic review. Psychiatry Research, 2022, 311, 114525.	3.3	5

#	Article	IF	CITATIONS
19	Underage drinking in Brazil: findings from a community household survey. Revista Brasileira De Psiquiatria, 2022, 44, 257-263.	1.7	3
20	Inflammatory and oxidative stress markers in post-traumatic stress disorder: a systematic review and meta-analysis. Molecular Psychiatry, 2022, 27, 3150-3163.	7.9	23
21	Biological underpinnings for the association between substance use and bipolar disorder. Bipolar Disorders, 2022, 24, 227-228.	1.9	0
22	Investigation of blood-brain barrier disruption in an animal model of mania induced by D-amphetamine. Journal of Affective Disorders Reports, 2022, 9, 100368.	1.7	1
23	Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs. European Neuropsychopharmacology, 2022, 60, 91-99.	0.7	9
24	<i>Letter to the Editor:</i> Antidepressant and Antisuicidal Effects of Esketamine in Adolescents with Major Depressive Disorder and Suicidal Ideation: A Case Series. Journal of Child and Adolescent Psychopharmacology, 2022, 32, 366-367.	1.3	3
25	Obesity and mixed features in bipolar disorder: A systematic review. Psychiatry Research Communications, 2022, 2, 100062.	1.0	1
26	The assessment of lifestyle changes during the COVID-19 pandemic using a multidimensional scale. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 16-26.	1.8	118
27	Lithium-induced neuroprotective activity in neuronal and microglial cells: A purinergic perspective. Psychiatry Research, 2021, 295, 113562.	3.3	5
28	History of suicide attempts in patients with bipolar disorder type I: socio-demographic and clinical factors, quality of life and functioning. Nordic Journal of Psychiatry, 2021, 75, 306-313.	1.3	11
29	Ketamine and Esketamine augmentation for suicidal ideation: A randomized, double-blinded clinical trial. General Hospital Psychiatry, 2021, 68, 97-99.	2.4	16
30	Association between vaping and health outcomes in patients with opioid use disorder: a systematic review protocol. BMJ Open, 2021, 11, e040349.	1.9	0
31	The assessment of lifestyle changes during the COVID-19 pandemic using a multidimensional scale. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 16-26.	0.3	5
32	Neuroprogression in post-traumatic stress disorder: a systematic review. Trends in Psychiatry and Psychotherapy, 2021, 43, 167-176.	0.8	4
33	Increase in serum brain-derived neurotrophic factor levels during early withdrawal in severe alcohol users. Trends in Psychiatry and Psychotherapy, 2021, , .	0.8	1
34	Biological Pathways Associated with Neuroprogression in Bipolar Disorder. Brain Sciences, 2021, 11, 228.	2.3	12
35	Translating science into policy: mental health challenges during the COVID-19 pandemic. Revista Brasileira De Psiquiatria, 2021, 43, 638-649.	1.7	12
36	Clozapine for bipolar disorder: What do we know so far and what next?. Bipolar Disorders, 2021, 23, 115-116.	1.9	9

#	Article	IF	CITATIONS
37	Effects of depression and excess body weight on cognition and functioning in young adults: A population-based study. Journal of Affective Disorders, 2021, 282, 401-406.	4.1	5
38	Sleep alterations in individuals recently diagnosed with bipolar disorder across different mood stages. Psychiatry Research, 2021, 299, 113824.	3.3	1
39	Cognitive complaints in individuals recently diagnosed with bipolar disorder: A cross-sectional study. Psychiatry Research, 2021, 300, 113894.	3.3	4
40	Predicting offenses among individuals with psychiatric disorders - A machine learning approach. Journal of Psychiatric Research, 2021, 138, 146-154.	3.1	20
41	Lifestyle in Undergraduate Students and Demographically Matched Controls during the COVID-19 Pandemic in Spain. International Journal of Environmental Research and Public Health, 2021, 18, 8133.	2.6	7
42	Intranasal esketamine and the dawn of precision psychiatry. Revista Brasileira De Psiquiatria, 2021, , .	1.7	1
43	Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force. Bipolar Disorders, 2021, 23, 659-678.	1.9	27
44	Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic. JAMA Network Open, 2021, 4, e2120603.	5.9	47
45	Bipolar disorder and frontotemporal dementia: A systematic review. Acta Psychiatrica Scandinavica, 2021, 144, 433-447.	4.5	9
46	Unveiling the neurobiology of learning and memory: the lifetime accomplishments of Ivan Izquierdo (1937-2021). Revista Brasileira De Psiquiatria, 2021, 43, 353-354.	1.7	0
47	Genetic basis of cannabis use: a systematic review. BMC Medical Genomics, 2021, 14, 203.	1.5	11
48	The cumulative effect of multiple dimensions of lifestyle on risky drinking during the Covid-19 pandemic. Preventive Medicine, 2021, 150, 106718.	3.4	8
49	Variations in seasonal solar insolation are associated with a history of suicide attempts in bipolar I disorder. International Journal of Bipolar Disorders, 2021, 9, 26.	2.2	6
50	Early illness progression in mood disorders: a population-based longitudinal study. Psychiatry Research, 2021, 306, 114225.	3.3	0
51	5-year incidence of suicide-risk in youth: A gradient tree boosting and SHAP study. Journal of Affective Disorders, 2021, 295, 1049-1056.	4.1	11
52	Lifestyle changes and mental health during the COVID-19 pandemic: A repeated, cross-sectional web survey. Journal of Affective Disorders, 2021, 295, 173-182.	4.1	32
53	Stigmatized individuals: a case for precision ethics. Trends in Psychiatry and Psychotherapy, 2021, , .	0.8	0
54	Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial. Trends in Psychiatry and Psychotherapy, 2021, , .	0.8	4

#	Article	IF	CITATIONS
55	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. Bipolar Disorders, 2021, 23, 767-788.	1.9	32
56	Substance use as a risk factor for bipolar disorder: A systematic review. Journal of Psychiatric Research, 2021, 144, 285-295.	3.1	15
57	Differential power of placebo across major psychiatric disorders: a preliminary meta-analysis and machine learning study. Scientific Reports, 2021, 11, 21301.	3.3	3
58	Adding science to the art of suicide prevention. Jornal Brasileiro De Psiquiatria, 2021, 70, 191-192.	0.7	0
59	Identifying patient-important outcomes for treatment of bipolar disorder: a systematic review protocol. BMJ Open, 2021, 11, e050453.	1.9	Ο
60	Current understandings of the trajectory and emerging correlates of cognitive impairment in bipolar disorder: An overview of evidence. Bipolar Disorders, 2020, 22, 13-27.	1.9	89
61	Emotional memory in bipolar disorder: Impact of multiple episodes and childhood trauma. Journal of Affective Disorders, 2020, 260, 206-213.	4.1	6
62	P2X7 Purinergic Receptor Is Involved in the Pathophysiology of Mania: a Preclinical Study. Molecular Neurobiology, 2020, 57, 1347-1360.	4.0	6
63	Gene Regulatory Network of Dorsolateral Prefrontal Cortex: a Master Regulator Analysis of Major Psychiatric Disorders. Molecular Neurobiology, 2020, 57, 1305-1316.	4.0	6
64	Differential biomarker signatures in unipolar and bipolar depression: A machine learning approach. Australian and New Zealand Journal of Psychiatry, 2020, 54, 393-401.	2.3	27
65	Clinical correlates of high burden of general medical comorbidities in patients with bipolar disorder. Journal of Affective Disorders Reports, 2020, 1, 100001.	1.7	Ο
66	CCL11 levels in drug-naive bipolar patients: The role of sex and smoking status. Journal of Affective Disorders Reports, 2020, 1, 100002.	1.7	1
67	Structural and Functional Brain Correlates of Neuroprogression in Bipolar Disorder. Current Topics in Behavioral Neurosciences, 2020, 48, 197-213.	1.7	9
68	GWAS-identified genetic variants associated with medication-assisted treatment outcomes in patients with opioid use disorder: a systematic review and meta-analysis protocol. Systematic Reviews, 2020, 9, 200.	5.3	1
69	Early identification of bipolar disorder among young adults – a 22â€year community birth cohort. Acta Psychiatrica Scandinavica, 2020, 142, 476-485.	4.5	16
70	Genetic determinants of cannabis use: a systematic review protocol. Systematic Reviews, 2020, 9, 190.	5.3	4
71	The Early Burden of Disability in Individuals With Mood and Other Common Mental Disorders in Ontario, Canada. JAMA Network Open, 2020, 3, e2020213.	5.9	27
72	Clozapine in bipolar disorder: A systematic review and meta-analysis. Journal of Psychiatric Research, 2020, 125, 21-27.	3.1	31

#	Article	IF	CITATIONS
73	Evaluation of BDNF as a Biomarker for Impulsivity in a Psychiatric Population. Diagnostics, 2020, 10, 419.	2.6	8
74	Emotional reactivity and explicit emotional memory biases in major depressive disorder during euthymia. Psychiatry Research, 2020, 285, 112847.	3.3	1
75	Mixed episodes and suicide risk: A community sample of young adults. Journal of Affective Disorders, 2020, 266, 252-257.	4.1	6
76	Risk of dementia in bipolar disorder and the interplay of lithium: a systematic review and metaâ€analyses. Acta Psychiatrica Scandinavica, 2020, 141, 510-521.	4.5	80
77	Resilience as a mediator factor in the relationship between childhood trauma and mood disorder: A community sample of young adults. Journal of Affective Disorders, 2020, 274, 48-53.	4.1	26
78	Lifestyle behaviours during the COVIDâ€19 – time to connect. Acta Psychiatrica Scandinavica, 2020, 141, 399-400.	4.5	183
79	Lifetime cocaine use is a potential predictor for conversion from major depressive disorder to bipolar disorder: A prospective study. Psychiatry and Clinical Neurosciences, 2020, 74, 418-423.	1.8	9
80	Effects of childhood trauma on BDNF and TBARS during crack-cocaine withdrawal. Revista Brasileira De Psiquiatria, 2020, 42, 214-217.	1.7	5
81	Peripheral Oxidative Stress Markers in Patients with Bipolar Disorder during Euthymia and in Siblings. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 77-86.	1.2	9
82	Depression, Anxiety, and Lifestyle Among Essential Workers: A Web Survey From Brazil and Spain During the COVID-19 Pandemic. Journal of Medical Internet Research, 2020, 22, e22835.	4.3	56
83	Differentiating irritable mood and disruptive behavior in adults. Trends in Psychiatry and Psychotherapy, 2020, 42, 375-386.	0.8	1
84	Metabolic syndrome, depression and anhedonia among young adults. Psychiatry Research, 2019, 271, 306-310.	3.3	31
85	Risk factors for suicidality in patients with panic disorder: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2019, 105, 34-38.	6.1	19
86	Machine learning and big data analytics in bipolar disorder: A position paper from the International Society for Bipolar Disorders Big Data Task Force. Bipolar Disorders, 2019, 21, 582-594.	1.9	74
87	Attenuated inflammatory response of monocyte-derived macrophage from patients with BD: a preliminary report. International Journal of Bipolar Disorders, 2019, 7, 13.	2.2	16
88	Clinical outcomes and childhood trauma in bipolar disorder: A community sample of young adults. Psychiatry Research, 2019, 275, 228-232.	3.3	20
89	S149. Gene Expression in Dorsolateral Prefrontal Cortex: A Master Regulator Analysis of Major Psychiatric Disorders. Biological Psychiatry, 2019, 85, S354.	1.3	0
90	Explicit emotional memory biases in mood disorders: A systematic review. Psychiatry Research, 2019, 278, 162-172.	3.3	12

#	Article	IF	CITATIONS
91	Anxiety disorders in childhood are associated with youth IL-6 levels: A mediation study including metabolic stress and childhood traumatic events. Journal of Psychiatric Research, 2019, 115, 43-50.	3.1	15
92	Adjunctive tianeptine treatment for bipolar disorder: A 24-week randomized, placebo-controlled, maintenance trial. Journal of Psychopharmacology, 2019, 33, 502-510.	4.0	12
93	Association between solar insolation and a history of suicide attempts in bipolar I disorder. Journal of Psychiatric Research, 2019, 113, 1-9.	3.1	25
94	Ndel1 oligopeptidase activity as a potential biomarker of early stages of schizophrenia. Schizophrenia Research, 2019, 208, 202-208.	2.0	14
95	Agmatine as a potential therapeutic intervention in bipolar depression: the preclinical landscape. Expert Opinion on Therapeutic Targets, 2019, 23, 327-339.	3.4	9
96	Big Data and Machine Learning Meet the Health Sciences. , 2019, , 1-13.		8
97	Subjective neurocognition and quality of life in patients with bipolar disorder and siblings. Journal of Affective Disorders, 2019, 245, 283-288.	4.1	21
98	Differences between unipolar mania and bipolarâ€I disorder: Evidence from nine epidemiological studies. Bipolar Disorders, 2019, 21, 437-448.	1.9	20
99	Metabolic syndrome and psychiatric disorders: a population-based study. Revista Brasileira De Psiquiatria, 2019, 41, 38-43.	1.7	25
100	Bipolar disorder and 1513A>C P2RX7 polymorphism frequency. Neuroscience Letters, 2019, 694, 143-147.	2.1	7
101	Age-related deficits in intracortical myelination in young adults with bipolar disorder type I. Journal of Psychiatry and Neuroscience, 2019, 44, 79-88.	2.4	14
102	Is bipolar disorder associated with premature aging?. Trends in Psychiatry and Psychotherapy, 2019, 41, 315-317.	0.8	4
103	The impact of body mass index in gene expression of reelin pathway mediators in individuals with schizophrenia and mood disorders: A post-mortem study. Journal of Psychiatric Research, 2018, 102, 186-191.	3.1	5
104	Bipolar disorder and tobacco smoking: Categorical and dimensional clinical correlates in subjects from the Brazilian bipolar research network. Comprehensive Psychiatry, 2018, 82, 14-21.	3.1	17
105	Mood disorders and prospective suicidality in young adults: a populationâ€based cohort study. Acta Psychiatrica Scandinavica, 2018, 137, 109-115.	4.5	14
106	Association of intracortical myelin and cognitive function in bipolar I disorder. Acta Psychiatrica Scandinavica, 2018, 138, 62-72.	4.5	13
107	Oxidative stress markers imbalance in late-life depression. Journal of Psychiatric Research, 2018, 102, 29-33.	3.1	45
108	Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 2018, 20, 97-170.	1.9	1,079

#	Article	IF	CITATIONS
109	The differential association between history of childhood sexual abuse and body mass index in early and late stages of bipolar disorder. Journal of Affective Disorders, 2018, 227, 214-218.	4.1	17
110	Risk Factors for Suicidality in Patients With Schizophrenia: A Systematic Review, Meta-analysis, and Meta-regression of 96 Studies. Schizophrenia Bulletin, 2018, 44, 787-797.	4.3	118
111	Case series of diagnostic shift from bipolar disorder to schizoaffective disorder. Nordic Journal of Psychiatry, 2018, 72, 232-235.	1.3	1
112	Resting-state functional connectivity in individuals with bipolar disorder during clinical remission: a systematic review. Journal of Psychiatry and Neuroscience, 2018, 43, 298-316.	2.4	106
113	Depression and Mania Induce Pro-inflammatory Activation of Macrophages Following Application of Serum from Individuals with Bipolar Disorder. Clinical Psychopharmacology and Neuroscience, 2018, 16, 103-108.	2.0	23
114	White matter volume is decreased in bipolar disorder at early and late stages. Trends in Psychiatry and Psychotherapy, 2018, 40, 277-284.	0.8	9
115	Toward Precision Psychiatry in Bipolar Disorder: Staging 2.0. Frontiers in Psychiatry, 2018, 9, 641.	2.6	79
116	Staging, Neurocognition and Social Functioning in Bipolar Disorder. Frontiers in Psychiatry, 2018, 9, 709.	2.6	21
117	Potential use of text classification tools as signatures of suicidal behavior: A proof-of-concept study using Virginia Woolf's personal writings. PLoS ONE, 2018, 13, e0204820.	2.5	15
118	Impact of resilience on the improvement of depressive symptoms after cognitive therapies for depression in a sample of young adults. Trends in Psychiatry and Psychotherapy, 2018, 40, 226-231.	0.8	14
119	Construction of a biological rhythm assessment scale for children. Trends in Psychiatry and Psychotherapy, 2018, 40, 53-60.	0.8	11
120	Volumetric brain magnetic resonance imaging predicts functioning in bipolar disorder: A machine learning approach. Journal of Psychiatric Research, 2018, 103, 237-243.	3.1	47
121	Emotional hyperâ€reactivity and cardiometabolic risk in remitted bipolar patients: a machine learning approach. Acta Psychiatrica Scandinavica, 2018, 138, 348-359.	4.5	19
122	Cardiovascular risk and bipolar disorder: factors associated with a positive coronary calcium score in patients with bipolar disorder type 1. Revista Brasileira De Psiquiatria, 2018, 40, 163-168.	1.7	7
123	EGR3 Immediate Early Gene and the Brain-Derived Neurotrophic Factor in Bipolar Disorder. Frontiers in Behavioral Neuroscience, 2018, 12, 15.	2.0	20
124	Mediator effects of parameters of inflammation and neurogenesis from a <i>N</i> -acetyl cysteine clinical-trial for bipolar depression. Acta Neuropsychiatrica, 2018, 30, 334-341.	2.1	16
125	Intracellular Pathogen Infections and Immune Response in Autism. NeuroImmunoModulation, 2018, 25, 271-279.	1.8	13
126	Neuron-glia Interaction as a Possible Pathophysiological Mechanism of Bipolar Disorder. Current Neuropharmacology, 2018, 16, 519-532.	2.9	45

#	Article	IF	CITATIONS
127	Validation of the Korean Version of the Biological Rhythms Interview of Assessment in Neuropsychiatry. Psychiatry Investigation, 2018, 15, 1115-1120.	1.6	14
128	Hippocampal neurochemical markers in bipolar disorder patients following the first-manic episode: A prospective 12-month proton magnetic resonance spectroscopy study. Australian and New Zealand Journal of Psychiatry, 2017, 51, 65-74.	2.3	9
129	Peripheral biomarker signatures of bipolar disorder and schizophrenia: A machine learning approach. Schizophrenia Research, 2017, 188, 182-184.	2.0	22
130	Functional impairment and cognitive performance in mood disorders: A community sample of young adults. Psychiatry Research, 2017, 251, 85-89.	3.3	13
131	Inflammatory cytokines and functional impairment in drug-free subjects with mood disorder. Journal of Neuroimmunology, 2017, 307, 33-36.	2.3	19
132	Telomere Length, Oxidative Stress, Inflammation and BDNF Levels in Siblings of Patients with Bipolar Disorder: Implications for Accelerated Cellular Aging. International Journal of Neuropsychopharmacology, 2017, 20, 445-454.	2.1	67
133	Clinical staging and serum cytokines in bipolar patients during euthymia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 77, 194-201.	4.8	37
134	509. EGR3 in Bipolar Disorder: Preliminary Results of an in Vitro Study for Validation of Bioinformatics Findings. Biological Psychiatry, 2017, 81, S207.	1.3	0
135	"Why throw away something useful?― Attitudes and opinions of people treated for bipolar disorder and their relatives on organ and tissue donation. Cell and Tissue Banking, 2017, 18, 105-117.	1.1	10
136	Should bipolar disorder treatment be modified depending on staging?. Expert Review of Neurotherapeutics, 2017, 17, 93-95.	2.8	8
137	Differences in biomarkers of crack-cocaine adolescent users before/after abstinence. Drug and Alcohol Dependence, 2017, 177, 207-213.	3.2	22
138	Metabolic syndrome in subjects with bipolar disorder and major depressive disorder in a current depressive episode: Population-based study. Journal of Psychiatric Research, 2017, 92, 119-123.	3.1	59
139	Inflammation and internalizing disorders in adolescents. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 77, 133-137.	4.8	22
140	Changing the bipolar illness trajectory. Lancet Psychiatry,the, 2017, 4, 11-13.	7.4	14
141	The impact of machine learning techniques in the study of bipolar disorder: A systematic review. Neuroscience and Biobehavioral Reviews, 2017, 80, 538-554.	6.1	146
142	Solar insolation in springtime influences age of onset of bipolar I disorder. Acta Psychiatrica Scandinavica, 2017, 136, 571-582.	4.5	24
143	Sudden unexpected death in bipolar disorder. Journal of Affective Disorders, 2017, 223, 8-9.	4.1	2
144	The Bipolar Illness Onset study: research protocol for the BIO cohort study. BMJ Open, 2017, 7, e015462.	1.9	119

#	Article	IF	CITATIONS
145	Serum of Bipolar Patients Induces Pro-inflammatory Activation of Macrophages. European Psychiatry, 2017, 41, S114-S114.	0.2	0
146	Neuroprogression and illness trajectories in bipolar disorder. Expert Review of Neurotherapeutics, 2017, 17, 277-285.	2.8	99
147	Mood disorders and biological rhythms in young adults: A large population-based study. Journal of Psychiatric Research, 2017, 84, 98-104.	3.1	53
148	Virginia Woolf, neuroprogression, and bipolar disorder. Revista Brasileira De Psiquiatria, 2017, 39, 69-71.	1.7	5
149	Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 1627-1632.	2.2	28
150	Cell therapy in the treatment of bipolar mania in an animal model: a proof of concept study. Trends in Psychiatry and Psychotherapy, 2017, 39, 196-201.	0.8	2
151	Frequency of brain tissue donation for research after suicide. Revista Brasileira De Psiquiatria, 2017, 39, 180-182.	1.7	5
152	Cytokine Levels in Panic Disorder: Evidence for a Dose-Response Relationship. Psychosomatic Medicine, 2017, 79, 126-132.	2.0	22
153	Analyzing leukocyte telomere length in bipolar disorder: Authors' reply. Revista Brasileira De Psiquiatria, 2017, 39, 275-276.	1.7	1
154	Clinical Outcomes Associated With Comorbid Posttraumatic Stress Disorder Among Patients With Bipolar Disorder. Journal of Clinical Psychiatry, 2016, 77, e555-e560.	2.2	13
155	Cognitive performance and psychosocial functioning in patients with bipolar disorder, unaffected siblings, and healthy controls. Revista Brasileira De Psiquiatria, 2016, 38, 275-280.	1.7	12
156	Challenges and developments in research of the early stages of bipolar disorder. Revista Brasileira De Psiquiatria, 2016, 38, 329-337.	1.7	10
157	Serum BDNF levels in unaffected first-degree relatives of patients with bipolar disorder. Revista Brasileira De Psiquiatria, 2016, 38, 197-200.	1.7	7
158	Psychiatric and clinical correlates of rapid cycling bipolar disorder: a cross-sectional study. Revista Brasileira De Psiquiatria, 2016, 38, 270-274.	1.7	17
159	Shortened telomere length in bipolar disorder: a comparison of the early and late stages of disease. Revista Brasileira De Psiquiatria, 2016, 38, 281-286.	1.7	43
160	The Biological Rhythms Interview of Assessment in Neuropsychiatry in patients with bipolar disorder: correlation with affective temperaments and schizotypy. Revista Brasileira De Psiquiatria, 2016, 38, 325-328.	1.7	10
161	The association between biological rhythms, depression, and functioning in bipolar disorder: a large multi enter study. Acta Psychiatrica Scandinavica, 2016, 133, 102-108.	4.5	66
162	Areas of controversy in neuroprogression in bipolar disorder. Acta Psychiatrica Scandinavica, 2016, 134, 91-103.	4.5	173

#	Article	IF	CITATIONS
163	Brainâ€derived neurotrophic factor, impaired glucose metabolism, and bipolar disorder course. Bipolar Disorders, 2016, 18, 373-378.	1.9	20
164	Antidepressants for generalised anxiety disorder (GAD). The Cochrane Library, 2016, 2016, CD003592.	2.8	1
165	<i>BDNF Val66Met</i> polymorphism and peripheral protein levels in pediatric bipolar disorder and attentionâ€deficit/hyperactivity disorder. Acta Psychiatrica Scandinavica, 2016, 134, 268-274.	4.5	15
166	A Study of Biological Rhythm Disturbances in Polish Remitted Bipolar Patients using the BRIAN, CSM, and SWPAQ Scales. Neuropsychobiology, 2016, 74, 125-130.	1.9	13
167	Antioxidant treatments for schizophrenia. The Cochrane Library, 2016, 2016, CD008919.	2.8	49
168	Evaluation of cytokines, oxidative stress markers and brain-derived neurotrophic factor in patients with fibromyalgia – A controlled cross-sectional study. Cytokine, 2016, 84, 25-28.	3.2	50
169	Differential expression of transcriptional regulatory units in the prefrontal cortex of patients with bipolar disorder: potential role of early growth response gene 3. Translational Psychiatry, 2016, 6, e805-e805.	4.8	28
170	Reduced Neurite Density in Neuronal Cell Cultures Exposed to Serum of Patients with Bipolar Disorder. International Journal of Neuropsychopharmacology, 2016, 19, pyw051.	2.1	7
171	The role of macrophage polarization on bipolar disorder: Identifying new therapeutic targets. Australian and New Zealand Journal of Psychiatry, 2016, 50, 618-630.	2.3	28
172	Peripheral adenosine levels in euthymic patients with bipolar disorder. Psychiatry Research, 2016, 246, 421-426.	3.3	28
173	High levels of brain-derived neurotrophic factor are associated with treatment adherence among crack-cocaine users. Neuroscience Letters, 2016, 630, 169-175.	2.1	13
174	Circadian preferences, oxidative stress and inflammatory cytokines in bipolar disorder: A community study. Journal of Neuroimmunology, 2016, 301, 23-29.	2.3	27
175	Biological rhythms, metabolic syndrome and current depressive episode in a community sample. Psychoneuroendocrinology, 2016, 72, 34-39.	2.7	17
176	Childhood trauma, family history, and their association with mood disorders in early adulthood. Acta Psychiatrica Scandinavica, 2016, 134, 281-286.	4.5	75
177	Role of P2X7 Receptor in an Animal Model of Mania Induced by D-Amphetamine. Molecular Neurobiology, 2016, 53, 611-620.	4.0	51
178	Big data analytics and machine learning: 2015 and beyond. Lancet Psychiatry,the, 2016, 3, 13-15.	7.4	110
179	Reduced hippocampus volume and memory performance in bipolar disorder patients carrying the BDNF val66met met allele. Journal of Affective Disorders, 2016, 198, 198-205.	4.1	80
180	Individualized Prediction and Clinical Staging of Bipolar Disorders Using Neuroanatomical Biomarkers. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2016, 1, 186-194.	1.5	58

#	Article	IF	CITATIONS
181	Post-traumatic stress disorder and interleukin 6 – Authors' reply. Lancet Psychiatry,the, 2016, 3, 202.	7.4	1
182	Glucocorticoid Receptors, Brain-Derived Neurotrophic Factor, Serotonin and Dopamine Neurotransmission are Associated with Interferon-Induced Depression. International Journal of Neuropsychopharmacology, 2016, 19, pyv135.	2.1	29
183	Hippocampal volume and verbal memory performance in late-stage bipolar disorder. Journal of Psychiatric Research, 2016, 73, 102-107.	3.1	95
184	Individualized identification of euthymic bipolar disorder using the Cambridge Neuropsychological Test Automated Battery (CANTAB) and machine learning. Journal of Affective Disorders, 2016, 192, 219-225.	4.1	39
185	Identifying a clinical signature of suicidality among patients with mood disorders: A pilot study using a machine learning approach. Journal of Affective Disorders, 2016, 193, 109-116.	4.1	152
186	Predictors of psychiatric readmission among patients with bipolar disorder at an academic safety-net hospital. Australian and New Zealand Journal of Psychiatry, 2016, 50, 584-593.	2.3	42
187	Refractory bipolar disorder and neuroprogression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 70, 103-110.	4.8	35
188	Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. Molecular Psychiatry, 2016, 21, 1050-1056.	7.9	42
189	Staging model raises fundamental questions about the nature of bipolar disorder. Journal of Psychiatry and Neuroscience, 2016, 41, 291-293.	2.4	12
190	Concepts and misconceptions regarding clinical staging models – Author response. Journal of Psychiatry and Neuroscience, 2016, 41, E84-E85.	2.4	1
191	Interaction between SLC6A4 promoter variants and childhood trauma on the age at onset of bipolar disorders. Scientific Reports, 2015, 5, 16301.	3.3	17
192	Rapid cycling bipolar disorder is associated with a higher lifetime prevalence of migraine. Acta Psychiatrica Scandinavica, 2015, 132, 308-309.	4.5	6
193	Neurotrophins, cytokines, oxidative parameters and funcionality in Progressive Muscular Dystrophies. Anais Da Academia Brasileira De Ciencias, 2015, 87, 1809-1818.	0.8	13
194	Bipolar disorder prevalence: a systematic review and meta-analysis of the literature. Revista Brasileira De Psiquiatria, 2015, 37, 155-161.	1.7	163
195	Quality of life, social functioning, family structure, and treatment history associated with crack cocaine use in youth from the general population. Revista Brasileira De Psiquiatria, 2015, 37, 211-218.	1.7	19
196	Mesenchymal stem cells for the treatment of neurodegenerative and psychiatric disorders. Anais Da Academia Brasileira De Ciencias, 2015, 87, 1435-1449.	0.8	27
197	Association of interleukin-10 levels with age of onset and duration of illness in patients with major depressive disorder. Revista Brasileira De Psiquiatria, 2015, 37, 296-302.	1.7	19
198	Association of serum brain-derived neurotrophic factor (BDNF) and tumor necrosis factor-alpha (TNF-α) with diagnosis of delirium in oncology inpatients. Revista Brasileira De Psiquiatria, 2015, 37, 197-202.	1.7	9

#	Article	lF	CITATIONS
199	Ethanol during adolescence decreased the BDNF levels in the hippocampus in adult male Wistar rats, but did not alter aggressive and anxiety-like behaviors. Trends in Psychiatry and Psychotherapy, 2015, 37, 143-151.	0.8	24
200	Correlation between Peripheral Levels of Brain-Derived Neurotrophic Factor and Hippocampal Volume in Children and Adolescents with Bipolar Disorder. Neural Plasticity, 2015, 2015, 1-7.	2.2	7
201	The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience, 2015, 300, 141-154.	2.3	496
202	Memory and brain-derived neurotrophic factor after subchronic or chronic amphetamine treatment in an animal model of mania. Journal of Psychiatric Research, 2015, 68, 329-336.	3.1	23
203	Differences in parental bonding between schizophrenia and bipolar disorder: Evidence of prodromal symptoms?. Schizophrenia Research, 2015, 165, 134-137.	2.0	7
204	Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. Lancet Psychiatry,the, 2015, 2, 1002-1012.	7.4	520
205	Developmental staging models in bipolar disorder. International Journal of Bipolar Disorders, 2015, 3, 33.	2.2	6
206	Influence of birth cohort on age of onset cluster analysis in bipolar I disorder. European Psychiatry, 2015, 30, 99-105.	0.2	28
207	Changes in the corpus callosum in women with late-stage bipolar disorder. Acta Psychiatrica Scandinavica, 2015, 131, 458-464.	4.5	58
208	The role of encoding strategies in contextual memory deficits in patients with bipolar disorder. Neuropsychological Rehabilitation, 2015, 25, 122-136.	1.6	6
209	Is bipolar disorder associated with accelerating aging? A meta-analysis of telomere length studies. Journal of Affective Disorders, 2015, 186, 241-248.	4.1	42
210	Biological rhythms in bipolar and depressive disorders: A community study with drug-naÃ ⁻ ve young adults. Journal of Affective Disorders, 2015, 186, 145-148.	4.1	58
211	Mitochondrial and Oxidative Stress Aspects in Hippocampus of Rats Submitted to Dietary n-3 Polyunsaturated Fatty Acid Deficiency After Exposure to Early Stress. Neurochemical Research, 2015, 40, 1870-1881.	3.3	10
212	ls religiosity a protective factor against suicidal behavior in bipolar I outpatients?. Journal of Affective Disorders, 2015, 186, 156-161.	4.1	27
213	Effects of a single bout of maximal aerobic exercise on BDNF in bipolar disorder: A gender-based response. Psychiatry Research, 2015, 229, 57-62.	3.3	27
214	Damageâ€associated molecular patterns and immune activation in bipolar disorder. Acta Psychiatrica Scandinavica, 2015, 132, 211-217.	4.5	41
215	Effects of sodium butyrate on aversive memory in rats submitted to sepsis. Neuroscience Letters, 2015, 595, 134-138.	2.1	28
216	Verbal episodic memory along the course of schizophrenia and bipolar disorder: A new perspective. European Neuropsychopharmacology, 2015, 25, 169-175.	0.7	31

#	Article	IF	CITATIONS
217	Effects of Mood Stabilizers on Brain Energy Metabolism in Mice Submitted to an Animal Model of Mania Induced by Paradoxical Sleep Deprivation. Neurochemical Research, 2015, 40, 1144-1152.	3.3	20
218	Treatment delay is associated with more episodes and more severe illness staging progression in patients with bipolar disorder. Psychiatry Research, 2015, 227, 372-373.	3.3	11
219	Wet minds, dry minds, and the future of psychiatry as a science. Acta Psychiatrica Scandinavica, 2015, 131, 7-8.	4.5	10
220	Influence of light exposure during early life on the age of onset of bipolar disorder. Journal of Psychiatric Research, 2015, 64, 1-8.	3.1	39
221	Neuroprogression and Cognitive Functioning in Bipolar Disorder: A Systematic Review. Current Psychiatry Reports, 2015, 17, 75.	4.5	115
222	Staging Models and Functional Outcomes in Bipolar Disorder: Clinical Implications. Current Treatment Options in Psychiatry, 2015, 2, 205-217.	1.9	5
223	Immune activation as a mediator of the gut-brain axis in manic episodes. Australian and New Zealand Journal of Psychiatry, 2015, 49, 1223-1223.	2.3	0
224	Hypothalamic-Pituitary-Adrenal Axis Dysfunction and Illness Progression in Bipolar Disorder. International Journal of Neuropsychopharmacology, 2015, 18, pyu043-pyu043.	2.1	61
225	Functioning in bipolar disorder with substance abuse/dependence in a community sample of young adults. Journal of Affective Disorders, 2015, 187, 179-182.	4.1	15
226	Brainâ€derived neurotrophic factor and inflammatory markers in schoolâ€aged children with early trauma. Acta Psychiatrica Scandinavica, 2015, 131, 360-368.	4.5	41
227	Psychophysiological correlates of cognitive deficits in family caregivers of patients with Alzheimer Disease. Neuroscience, 2015, 286, 371-382.	2.3	53
228	Folic acid prevented cognitive impairment in experimental pneumococcal meningitis. Journal of Neural Transmission, 2015, 122, 643-651.	2.8	14
229	Cannabidiol Exposure During Neuronal Differentiation Sensitizes Cells Against Redox-Active Neurotoxins. Molecular Neurobiology, 2015, 52, 26-37.	4.0	30
230	Intracerebral Administration of BDNF Protects Rat Brain Against Oxidative Stress Induced by Ouabain in an Animal Model of Mania. Molecular Neurobiology, 2015, 52, 353-362.	4.0	34
231	Long-lasting recognition memory impairment and alterations in brain levels of cytokines and BDNF induced by maternal deprivation: effects of valproic acid and topiramate. Journal of Neural Transmission, 2015, 122, 709-719.	2.8	49
232	Cognitive and psychosocial impairment in remitted bipolar patients. Psicodebate, 2015, 14, 25.	0.4	2
233	C-Reactive Protein Alterations in Bipolar Disorder. Journal of Clinical Psychiatry, 2015, 76, 142-150.	2.2	136
234	Histone deacetylase activity and brain-derived neurotrophic factor (BDNF) levels in a pharmacological model of mania. Revista Brasileira De Psiquiatria, 2014, 36, 39-46.	1.7	32

#	Article	IF	CITATIONS
235	Socio-demographic and clinical characteristics of pregnant and puerperal crack-cocaine using women: preliminary data. Revista De Psiquiatria Clinica, 2014, 41, 121-123.	0.6	5
236	Increase in brain-derived neurotrophic factor expression in early crack cocaine withdrawal. International Journal of Neuropsychopharmacology, 2014, 17, 33-40.	2.1	40
237	Effectiveness and tolerance of antiâ€inflammatory drugs' addâ€on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatrica Scandinavica, 2014, 129, 163-179.	4.5	140
238	Burden and related factors in caregivers of young adults presenting bipolar and unipolar mood disorder. International Journal of Social Psychiatry, 2014, 60, 396-402.	3.1	17
239	Early apoptosis in peripheral blood mononuclear cells from patients with bipolar disorder. Journal of Affective Disorders, 2014, 152-154, 474-477.	4.1	26
240	Psychiatric and substance-use comorbidities associated with lifetime crack cocaine use in young adults in the general population. Comprehensive Psychiatry, 2014, 55, 1369-1376.	3.1	84
241	Inflammatory mediators of cognitive impairment in bipolar disorder. Journal of Psychiatric Research, 2014, 56, 18-27.	3.1	96
242	Val66Met polymorphism and serum brainâ€derived neurotrophic factor in bipolar disorder: an openâ€label trial. Acta Psychiatrica Scandinavica, 2014, 129, 393-400.	4.5	23
243	Gender-based differences in oxidative stress parameters do not underlie the differences in mood disorders susceptibility between sexes. European Psychiatry, 2014, 29, 58-63.	0.2	46
244	Violent and sexual behaviors and lifetime use of crack cocaine: a population-based study in Brazil. Social Psychiatry and Psychiatric Epidemiology, 2014, 49, 1249-1255.	3.1	33
245	Association between family history of mood disorders and clinical characteristics of bipolar disorder: Results from the Brazilian bipolar research network. Journal of Affective Disorders, 2014, 161, 104-108.	4.1	15
246	Staging bipolar disorder: clinical, biochemical, and functional correlates. Acta Psychiatrica Scandinavica, 2014, 129, 437-444.	4.5	84
247	Staging systems in bipolar disorder: an <scp>I</scp> nternational <scp>S</scp> ociety for <scp>B</scp> ipolar <scp>D</scp> isorders <scp>T</scp> ask <scp>F</scp> orce <scp>R</scp> eport. Acta Psychiatrica Scandinavica, 2014, 130, 354-363.	4.5	175
248	Vitamin B6 prevents cognitive impairment in experimental pneumococcal meningitis. Experimental Biology and Medicine, 2014, 239, 1360-1365.	2.4	15
249	P.2.d.033 Staging bipolar disorder: biological, clinical and functional correlates. European Neuropsychopharmacology, 2014, 24, S432-S433.	0.7	0
250	Mineralocorticoid receptor genotype moderates the association between physical neglect and serum BDNF. Journal of Psychiatric Research, 2014, 59, 8-13.	3.1	12
251	P.2.c.005 Use of mesenchymal stem cells as a novel treatment for bipolar disorder: preliminary results of an in vitro study. European Neuropsychopharmacology, 2014, 24, S410.	0.7	0
252	P.2.c.009 Epigenetically-induced modulation of the stress axis associated with the progression of bipolar disorder. European Neuropsychopharmacology, 2014, 24, S412-S413.	0.7	0

#	Article	IF	CITATIONS
253	Shared clinical associations between obesity and impulsivity in rapid cycling bipolar disorder: A systematic review. Journal of Affective Disorders, 2014, 168, 306-313.	4.1	19
254	Common biological mechanisms between bipolar disorder and type 2 diabetes: Focus on inflammation. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 54, 289-298.	4.8	28
255	Oxidative stress and BDNF as possible markers for the severity of crack cocaine use in early withdrawal. Psychopharmacology, 2014, 231, 4031-4039.	3.1	50
256	Correlation between n-3 polyunsaturated fatty acids consumption and BDNF peripheral levels in adolescents. Lipids in Health and Disease, 2014, 13, 44.	3.0	24
257	BDNF: A biomarker for social vulnerability in individuals diagnosed with gender dysphoria. Journal of Psychiatric Research, 2014, 50, 16-17.	3.1	4
258	Peripheral eotaxin-1 (CCL11) levels and mood disorder diagnosis in a population-based sample of young adults. Journal of Psychiatric Research, 2014, 48, 13-15.	3.1	27
259	Prevalence and clinical correlates of alcohol use disorders among bipolar disorder patients: Results from the Brazilian Bipolar Research Network. Comprehensive Psychiatry, 2014, 55, 1116-1121.	3.1	33
260	Progesterone and its metabolites as therapeutic targets in psychiatric disorders. Expert Opinion on Therapeutic Targets, 2014, 18, 679-690.	3.4	25
261	Relationship between sunlight and the age of onset of bipolar disorder: An international multisite study. Journal of Affective Disorders, 2014, 167, 104-111.	4.1	43
262	Clinical Staging in Bipolar Disorder. Journal of Clinical Psychiatry, 2014, 75, e450-e456.	2.2	125
263	Neurocognitive Functioning in Overweight and Obese Patients with Bipolar Disorder: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). Canadian Journal of Psychiatry, 2014, 59, 639-648.	1.9	18
264	Impaired endoplasmic reticulum stress response in bipolar disorder: cellular evidence of illness progression. International Journal of Neuropsychopharmacology, 2014, 17, 1453-1463.	2.1	58
265	Neuroprogression and staging in psychiatry: historical considerations. Revista Brasileira De Psiquiatria, 2014, 36, 187-188.	1.7	12
266	Validation of the Italian Version of the Biological Rhythms Interview of Assessment in Neuropsychiatry (BRIAN): Some Considerations on its Screening Usefulness. Clinical Practice and Epidemiology in Mental Health, 2014, 10, 48-52.	1.2	30
267	Daytime sleepiness, sleep disturbance and functioning impairment in bipolar disorder. Acta Neuropsychiatrica, 2013, 25, 101-104.	2.1	16
268	Plasma brain-derived neurotrophic factor levels, learning capacity and cognition in patients with first episode psychosis. BMC Psychiatry, 2013, 13, 27.	2.6	34
269	Biological rhythm disturbance in remitted bipolar patients. International Journal of Bipolar Disorders, 2013, 1, 6.	2.2	43
270	Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder. Expert Review of Neurotherapeutics, 2013, 13, 827-842.	2.8	57

#	Article	IF	CITATIONS
271	Validity and reliability of a rating scale on subjective cognitive deficits in bipolar disorder (COBRA). Journal of Affective Disorders, 2013, 150, 29-36.	4.1	116
272	Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Australian and New Zealand Journal of Psychiatry, 2013, 47, 321-332.	2.3	193
273	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. American Journal of Psychiatry, 2013, 170, 1249-1262.	7.2	579
274	Ketamine and imipramine in the nucleus accumbens regulate histone deacetylation induced by maternal deprivation and are critical for associated behaviors. Behavioural Brain Research, 2013, 256, 451-456.	2.2	63
275	Imipramine reverses alterations in cytokines and BDNF levels induced by maternal deprivation in adult rats. Behavioural Brain Research, 2013, 242, 40-46.	2.2	63
276	Mitochondrial activity and oxidative stress markers in peripheral blood mononuclear cells of patients with bipolar disorder, schizophrenia, and healthy subjects. Journal of Psychiatric Research, 2013, 47, 1396-1402.	3.1	92
277	Staging and Neuroprogression in Bipolar Disorder: A Systematic Review of the Literature. Revista Brasileira De Psiquiatria, 2013, 35, 70-74.	1.7	97
278	Modafinil ameliorates cognitive deficits induced by maternal separation and sleep deprivation. Behavioural Brain Research, 2013, 253, 274-279.	2.2	22
279	Serum concentrations of brain-derived neurotrophic factor in patients with gender identity disorder. Journal of Psychiatric Research, 2013, 47, 1546-1548.	3.1	16
280	Vulnerability to dietary n-3 polyunsaturated fatty acid deficiency after exposure to early stress in rats. Pharmacology Biochemistry and Behavior, 2013, 107, 11-19.	2.9	24
281	Peripheral toxicity in crack cocaine use disorders. Neuroscience Letters, 2013, 544, 80-84.	2.1	51
282	The Clinical Implications Of Cognitive Impairment and Allostatic Load in Bipolar Disorder. European Psychiatry, 2013, 28, 21-29.	0.2	119
283	Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Current Opinion in Psychiatry, 2013, 26, 19-26.	6.3	160
284	Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value. British Journal of Psychiatry, 2013, 202, 243-245.	2.8	204
285	Soft Bipolar Spectrum and Staging in Bipolar Disorder. Current Psychiatry Reviews, 2013, 9, 33-40.	0.9	0
286	Correlation of Acute Phase Inflammatory and Oxidative Markers With Long-term Cognitive Impairment in Sepsis Survivors Rats. Shock, 2013, 40, 45-48.	2.1	34
287	Bipolar Disorder Affects Behavior and Social Skills on the Internet. PLoS ONE, 2013, 8, e79673.	2.5	11
288	Expression of matrix metalloproteinases in patients with bipolar disorder. Revista Brasileira De Psiquiatria, 2013, 35, 375-379.	1.7	5

17

#	Article	IF	CITATIONS
289	Ketamine alters behavior and decreases BDNF levels in the rat brain as a function of time after drug administration. Revista Brasileira De Psiquiatria, 2013, 35, 262-266.	1.7	36
290	Cardiovascular risk factors in outpatients with bipolar disorder: a report from the Brazilian Research Network in Bipolar Disorder. Revista Brasileira De Psiquiatria, 2013, 35, 126-130.	1.7	31
291	Homocysteine and other markers of cardiovascular risk during a manic episode in patients with bipolar disorder. Revista Brasileira De Psiquiatria, 2013, 35, 157-160.	1.7	17
292	Early Life Stress Interacts with the Diet Deficiency of Omega-3 Fatty Acids during the Life Course Increasing the Metabolic Vulnerability in Adult Rats. PLoS ONE, 2013, 8, e62031.	2.5	34
293	The quest for better diagnosis: DSM-5 or RDoC?. Revista Brasileira De Psiquiatria, 2013, 35, 109-110.	1.7	3
294	RBP and Brazilian science. Revista Brasileira De Psiquiatria, 2013, 35, 337-337.	1.7	1
295	Soft Bipolar Spectrum and Staging in Bipolar Disorder. Current Psychiatry Reviews, 2013, 9, 33-40.	0.9	1
296	Peripheral oxidative damage in early-stage mood disorders: a nested population-based case-control study. International Journal of Neuropsychopharmacology, 2012, 15, 1043-1050.	2.1	58
297	Protein Kinase C and Oxidative Stress in an Animal Model of Mania. Current Neurovascular Research, 2012, 9, 47-57.	1.1	25
298	Anatomical faces of neuroprogression in bipolar disorder. Neuropsychiatry, 2012, 2, 279-280.	0.4	2
299	A Bidimensional Solution for Outcomes in Bipolar Disorder. Journal of Nervous and Mental Disease, 2012, 200, 180-182.	1.0	2
300	Staging and Neuroprogression in Bipolar Disorder. Current Psychiatry Reports, 2012, 14, 667-675.	4.5	101
301	Peripheral brain-derived neurotrophic factor changes along treatment with extended release quetiapine during acute mood episodes: An open-label trial in drug-free patients with bipolar disorder. Journal of Psychiatric Research, 2012, 46, 1511-1514.	3.1	32
302	Tianeptine exerts neuroprotective effects in the brain tissue of rats exposed to the chronic stress model. Pharmacology Biochemistry and Behavior, 2012, 103, 395-402.	2.9	33
303	P.2.e.027 Interleukin-6 as a biomarker of the model of staging in bipolar disorder. European Neuropsychopharmacology, 2012, 22, S291-S292.	0.7	0
304	Prevalence and clinical impact of eating disorders in bipolar patients. Revista Brasileira De Psiquiatria, 2012, 34, 66-70.	1.7	19
305	Screening for bipolar disorder in the primary care: A Brazilian survey. Journal of Affective Disorders, 2012, 143, 118-124.	4.1	13
306	Increased serum levels of C3 and C4 in patients with schizophrenia compared to eutymic patients with bipolar disorder and healthy. Revista Brasileira De Psiquiatria, 2012, 34, 119-120.	1.7	2

#	Article	IF	CITATIONS
307	Dopamine sudden depletion as a model for mixed depression. Medical Hypotheses, 2012, 78, 107-112.	1.5	12
308	Effects of experimental cerebral malaria in memory, brain-derived neurotrophic factor and acetylcholinesterase acitivity in the hippocampus of survivor mice. Neuroscience Letters, 2012, 523, 104-107.	2.1	22
309	Childhood trauma, impulsivity, and executive functioning in crack cocaine users. Comprehensive Psychiatry, 2012, 53, 238-244.	3.1	57
310	Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial. BMC Medicine, 2012, 10, 91.	5.5	81
311	Impact of comorbid migraine on the clinical course of bipolar disorder. Comprehensive Psychiatry, 2012, 53, 809-812.	3.1	25
312	Cognitive impairment in school-aged children with early trauma. Comprehensive Psychiatry, 2012, 53, 758-764.	3.1	86
313	The Relevance of Neuroscience Research Networks for Brazilian Science. Revista Brasileira De Psiquiatria, 2012, 34, 119-120.	1.7	0
314	Concurrent Validity and Reliability of the Brazilian Version of the Functioning Assessment Short Test in Patients with Schizophrenia. Value in Health Regional Issues, 2012, 1, 244-247.	1.2	14
315	Early functional impairment in bipolar youth: A nested population-based case-control study. Journal of Affective Disorders, 2012, 142, 208-212.	4.1	37
316	Associations between parenting behavior and anxiety in a rodent model and a clinical sample: relationship to peripheral BDNF levels. Translational Psychiatry, 2012, 2, e195-e195.	4.8	80
317	Marcadores periféricos e a fisiopatologia do transtorno bipolar. Revista De Psiquiatria Clinica, 2012, 39, 60-67.	0.6	14
318	Memory mood congruency phenomenon in bipolar I disorder and major depression disorder patients. Brazilian Journal of Medical and Biological Research, 2012, 45, 856-861.	1.5	4
319	Decreased BDNF levels in amygdala and hippocampus after intracerebroventricular administration of ouabain. Revista De Psiquiatria Clinica, 2012, 39, 157-160.	0.6	3
320	Imipramine treatment reverses depressiveâ€like behavior in alloxanâ€diabetic rats. Diabetes/Metabolism Research and Reviews, 2012, 28, 139-144.	4.0	27
321	Memantine treatment reverses anhedonia, normalizes corticosterone levels and increases BDNF levels in the prefrontal cortex induced by chronic mild stress in rats. Metabolic Brain Disease, 2012, 27, 175-182.	2.9	74
322	Early life stress exacerbates cognitive dysfunction induced by d-amphetamine: amelioration by valproic acid. Journal of Neural Transmission, 2012, 119, 627-637.	2.8	8
323	Social phobia in Brazilian university students: Prevalence, under-recognition and academic impairment in women. Journal of Affective Disorders, 2012, 136, 857-861.	4.1	57
324	Is there an association between suicide attempt and delay of initiation of mood stabilizers in bipolar I disorder?. Journal of Affective Disorders, 2012, 136, 1082-1087.	4.1	26

#	Article	IF	CITATIONS
325	Towards a multifactorial approach for prediction of bipolar disorder in at risk populations. Journal of Affective Disorders, 2012, 140, 82-91.	4.1	85
326	Stigma experiences in bipolar patients: the impact upon functioning. Journal of Psychiatric and Mental Health Nursing, 2012, 19, 665-671.	2.1	24
327	Illness burden and medical comorbidity in the Systematic Treatment Enhancement Program for Bipolar Disorder. Acta Psychiatrica Scandinavica, 2012, 125, 303-308.	4.5	78
328	Increased levels of adipokines in bipolar disorder. Journal of Psychiatric Research, 2012, 46, 389-393.	3.1	72
329	Neurobiological correlates of illness progression in the recurrent affective disorders. Journal of Psychiatric Research, 2012, 46, 561-573.	3.1	124
330	Similarities in serum oxidative stress markers and inflammatory cytokines inÂpatients with overt schizophrenia at early and late stages of chronicity. Journal of Psychiatric Research, 2012, 46, 819-824.	3.1	130
331	Mediators of allostasis and systemic toxicity in bipolar disorder. Physiology and Behavior, 2012, 106, 46-50.	2.1	100
332	Impact of sunlight on the age of onset of bipolar disorder. Bipolar Disorders, 2012, 14, 654-663.	1.9	39
333	Increased serum levels of C3 and C4 in patients with schizophrenia compared to eutymic patients with bipolar disorder and healthy. Revista Brasileira De Psiquiatria, 2012, 34, 119-120.	1.7	37
334	Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania. Journal of Psychopharmacology, 2011, 25, 274-280.	4.0	66
335	Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-NaÃ ⁻ ve Social Phobia Patients. Neuropsychopharmacology, 2011, 36, 1219-1226.	5.4	585
336	Insulin dysfunction and allostatic load in bipolar disorder. Expert Review of Neurotherapeutics, 2011, 11, 1017-1028.	2.8	54
337	Assessment of Executive Functions in a Brazilian Sample of Bipolar Subjects. Spanish Journal of Psychology, 2011, 14, 859-868.	2.1	2
338	Therapeutic use of omega-3 fatty acids in bipolar disorder. Expert Review of Neurotherapeutics, 2011, 11, 1029-1047.	2.8	87
339	Early life stress decreases hippocampal BDNF content and exacerbates recognition memory deficits induced by repeated d-amphetamine exposure. Behavioural Brain Research, 2011, 224, 100-106.	2.2	40
340	Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: A positive correlation. Neuroscience Letters, 2011, 491, 207-210.	2.1	59
341	Olanzapine plus fluoxetine treatment increases Nt-3 protein levels in the rat prefrontal cortex. Neuroscience Letters, 2011, 497, 99-103.	2.1	16
342	Effects of increased opportunity for physical exercise and learning experiences on recognition memory and brain-derived neurotrophic factor levels in brain and serum of rats. Neuroscience, 2011, 199, 284-291.	2.3	24

#	Article	IF	CITATIONS
343	The impact of a history of psychotic symptoms on cognitive function in euthymic bipolar patients: a comparison with schizophrenic patients and healthy controls. Revista Brasileira De Psiquiatria, 2011, 33, 353-361.	1.7	29
344	Creatine kinase levels in patients with bipolar disorder: depressive, manic, and euthymic phases. Revista Brasileira De Psiquiatria, 2011, 33, 171-175.	1.7	14
345	Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Revista Brasileira De Psiquiatria, 2011, 33, 268-274.	1.7	131
346	Association study of tryptophan hydroxylase 2 gene polymorphisms in bipolar disorder patients with panic disorder comorbidity. Psychiatric Genetics, 2011, 21, 106-111.	1.1	17
347	Behavioral and neurochemical effects of sodium butyrate in an animal model of mania. Behavioural Pharmacology, 2011, 22, 766-772.	1.7	65
348	Sixâ€month functional outcome of a bipolar disorder cohort in the context of a specializedâ€care program. Bipolar Disorders, 2011, 13, 679-686.	1.9	67
349	Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdala. Acta Neuropsychiatrica, 2011, 23, 241-248.	2.1	62
350	Brain-derived neurotrophic factor and neuron-specific enolase, but not S100β, levels are associated to the occurrence of delirium in intensive care unit patients. Journal of Critical Care, 2011, 26, 133-137.	2.2	69
351	Acute low dose of MK-801 prevents memory deficits without altering hippocampal DARPP-32 expression and BDNF levels in sepsis survivor rats. Journal of Neuroimmunology, 2011, 230, 48-51.	2.3	19
352	Peripheral biomarkers and illness activity in bipolar disorder. Journal of Psychiatric Research, 2011, 45, 156-161.	3.1	208
353	Cognitive abilities and clinical variables in bipolar I depressed and euthymic patients and controls. Journal of Psychiatric Research, 2011, 45, 495-504.	3.1	22
354	Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: A systematic review and meta-regression analysis. Journal of Psychiatric Research, 2011, 45, 995-1004.	3.1	349
355	Systemic toxicity in early-stage mood disorders. Journal of Psychiatric Research, 2011, 45, 1407-1409.	3.1	16
356	Tamoxifen effects on respiratory chain complexes and creatine kinase activities in an animal model of mania. Pharmacology Biochemistry and Behavior, 2011, 98, 304-310.	2.9	29
357	Stigma and functioning in patients with bipolar disorder. Journal of Affective Disorders, 2011, 130, 323-327.	4.1	70
358	Risk of suicide and mixed episode in men in the postpartum period. Journal of Affective Disorders, 2011, 132, 243-246.	4.1	46
359	The identification of unipolar mania subtype based on anxiety comorbidity. Journal of Affective Disorders, 2011, 132, 356-359.	4.1	17
360	The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial. Journal of Affective Disorders, 2011, 135, 389-394.	4.1	162

#	Article	IF	CITATIONS
361	Maternal Deprivation Induces Depressive-like Behaviour and Alters Neurotrophin Levels in the Rat Brain. Neurochemical Research, 2011, 36, 460-466.	3.3	87
362	Total and Mitochondrial Nitrosative Stress, Decreased Brain-Derived Neurotrophic Factor (BDNF) Levels and Glutamate Uptake, and Evidence of Endoplasmic Reticulum Stress in the Hippocampus of Vitamin A-Treated Rats. Neurochemical Research, 2011, 36, 506-517.	3.3	23
363	Neuroanatomical Profile of Antimaniac Effects of Histone Deacetylases Inhibitors. Molecular Neurobiology, 2011, 43, 207-214.	4.0	41
364	Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience and Biobehavioral Reviews, 2011, 35, 804-817.	6.1	1,007
365	Should bipolar disorder be considered a systemic illness?. Neuropsychiatry, 2011, 1, 45-54.	0.4	3
366	Improvement of behavioural and manic-like symptoms secondary to herpes simplex virus encephalitis with mood stabilizers: a case report. International Journal of Neuropsychopharmacology, 2011, 14, 718-720.	2.1	2
367	Symptom Dimensional Approach and BDNF in Unmedicated Obsessive-Compulsive Patients: <i>An Exploratory Study</i> . CNS Spectrums, 2011, 16, 179-189.	1.2	22
368	N-acetylcysteine as a mitochondrial enhancer: a new class of psychoactive drugs?. Revista Brasileira De Psiquiatria, 2011, 33, 321-322.	1.7	13
369	Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Revista Brasileira De Psiquiatria, 2011, 33, 268-274.	1.7	102
370	Sleep and Circadian Rhythm Disturbances in Bipolar Disorder. Journal of Clinical Psychiatry, 2011, 72, 724.	2.2	9
371	Effects of a gastrin-releasing peptide receptor antagonist on d-amphetamine-induced oxidative stress in the rat brain. Journal of Neural Transmission, 2010, 117, 309-316.	2.8	7
372	Chronic administration of harmine elicits antidepressant-like effects and increases BDNF levels in rat hippocampus. Journal of Neural Transmission, 2010, 117, 1131-1137.	2.8	85
373	Depressive-Like Parameters in Sepsis Survivor Rats. Neurotoxicity Research, 2010, 17, 279-286.	2.7	28
374	BDNF and PDE4, but not the GRPR, Regulate Viability of Human Medulloblastoma Cells. Journal of Molecular Neuroscience, 2010, 40, 303-310.	2.3	34
375	Circadian preference in bipolar disorder. Sleep and Breathing, 2010, 14, 153-155.	1.7	95
376	Correlation between behavioral deficits and decreased brain-derived neurotrofic factor in neonatal meningitis. Journal of Neuroimmunology, 2010, 223, 73-76.	2.3	32
377	Functional impact of biological rhythm disturbance in bipolar disorder. Journal of Psychiatric Research, 2010, 44, 220-223.	3.1	70
378	Association of polymorphisms of the tryptophan hydroxylase 2 gene with risk for bipolar disorder or suicidal behavior. Journal of Psychiatric Research, 2010, 44, 271-274.	3.1	17

#	Article	IF	CITATIONS
379	Effects of mood stabilizers on hippocampus and amygdala BDNF levels in an animal model of mania induced by ouabain. Journal of Psychiatric Research, 2010, 44, 506-510.	3.1	88
380	Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. Journal of Psychiatric Research, 2010, 44, 561-565.	3.1	44
381	Impairment of the mitochondrial electron transport chain due to sleep deprivation in mice. Journal of Psychiatric Research, 2010, 44, 775-780.	3.1	48
382	Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. Journal of Psychiatric Research, 2010, 44, 903-909.	3.1	101
383	Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies. Brain Research, 2010, 1337, 85-94.	2.2	317
384	The impact of comorbid posttraumatic stress disorder on bipolar disorder patients. Journal of Affective Disorders, 2010, 123, 71-76.	4.1	62
385	The impact of staging bipolar disorder on treatment outcome of family psychoeducation. Journal of Affective Disorders, 2010, 123, 81-86.	4.1	101
386	Plasma Brain-Derived-Neurotrophic Factor levels and cognitive function in euthymic bipolar type I patients. Annals of General Psychiatry, 2010, 9, .	2.7	0
387	Functional Impairment and Disability across Mood States in Bipolar Disorder. Value in Health, 2010, 13, 984-988.	0.3	161
388	Obesity is associated with previous suicide attempts in bipolar disorder. Acta Neuropsychiatrica, 2010, 22, 63-67.	2.1	38
389	Validity of the Portuguese version of the Bipolar Depression Rating Scale. Acta Neuropsychiatrica, 2010, 22, 100-101.	2.1	2
390	A systemic toxicity index developed to assess peripheral changes in mood episodes. Molecular Psychiatry, 2010, 15, 784-786.	7.9	105
391	Improvement of schizophrenia with electroconvulsive therapy and serum brainâ€derived neurotrophic factor levels: Lack of association in a pilot study. Psychiatry and Clinical Neurosciences, 2010, 64, 663-665.	1.8	11
392	The Role of BDNF as a Mediator of Neuroplasticity in Bipolar Disorder. Psychiatry Investigation, 2010, 7, 243.	1.6	124
393	BDNF/TrkB Content and Interaction with Gastrin-Releasing Peptide Receptor Blockade in Colorectal Cancer. Oncology, 2010, 79, 430-439.	1.9	50
394	Effects of moderate exercise on cigarette smoke exposure-induced hippocampal oxidative stress values and neurological behaviors in mice. Neuroscience Letters, 2010, 475, 16-19.	2.1	35
395	Effects of β-carboline harmine on behavioral and physiological parameters observed in the chronic mild stress model: Further evidence of antidepressant properties. Brain Research Bulletin, 2010, 81, 491-496.	3.0	84
396	Neurochemical and behavioural effects of acute and chronic memantine administration in rats: Further support for NMDA as a new pharmacological target for the treatment of depression?. Brain Research Bulletin, 2010, 81, 585-589.	3.0	97

#	Article	IF	CITATIONS
397	Correlates and impact of obsessive-compulsive comorbidity in bipolar disorder. Comprehensive Psychiatry, 2010, 51, 353-356.	3.1	55
398	Serum brain-derived neurotrophic factor in patients with trauma psychopathology. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 459-462.	4.8	67
399	Ketamine impairs recognition memory consolidation and prevents learning-induced increase in hippocampal brain-derived neurotrophic factor levels. Neuroscience, 2010, 167, 969-973.	2.3	115
400	Resistência à insulina e sÃndrome metabólica em pacientes ambulatoriais com transtorno do humor bipolar. Revista De Psiquiatria Clinica, 2010, 37, 81-84.	0.6	3
401	Instituto Nacional de Ciência e Tecnologia em Medicina Translacional (INCT-TM): abordagens metodológicas. Revista Brasileira De Psiquiatria, 2010, 32, 83-90.	1.7	13
402	Quality of Life in Bipolar Disorder. , 2010, , 3591-3606.		1
403	The Gastrin-Releasing Peptide Receptor as a Therapeutic Target in CNS Disorders. , 2010, , 390-399.		0
404	From neuroprogression to neuroprotection: implications for clinical care. Medical Journal of Australia, 2010, 193, S36-40.	1.7	68
405	Brain-derived neurotrophic factor gene val66met polymorphism and executive functioning in patients with bipolar disorder. Revista Brasileira De Psiquiatria, 2009, 31, 136-140.	1.7	20
406	Bipolar disorder and age-related functional impairment. Revista Brasileira De Psiquiatria, 2009, 31, 354-357.	1.7	18
407	Pilot-project of implantation of pharmaceutical care close to the program of bipolar mood disorder of the Hospital of Clinics of Porto Alegre. Brazilian Journal of Pharmaceutical Sciences, 2009, 45, 249-256.	1.2	2
408	Increased serum neurotrophin-4/5 levels in bipolar disorder. Journal of Psychiatric Research, 2009, 43, 721-723.	3.1	46
409	Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. Journal of Psychiatric Research, 2009, 43, 1171-1174.	3.1	101
410	Serum brain-derived neurotrophic factor in bipolar and unipolar depression: A potential adjunctive tool for differential diagnosis. Journal of Psychiatric Research, 2009, 43, 1200-1204.	3.1	111
411	Electrophysiological correlates of sleep disturbance induced by acute and chronic administration of d-amphetamine. Brain Research, 2009, 1249, 162-172.	2.2	11
412	Serum homocysteine levels and cognitive functioning in euthymic bipolar patients. Journal of Affective Disorders, 2009, 113, 285-290.	4.1	25
413	Early intervention in bipolar disorders: Clinical, biochemical and neuroimaging imperatives. Journal of Affective Disorders, 2009, 114, 1-13.	4.1	75
414	Development and use of a biological rhythm interview. Journal of Affective Disorders, 2009, 118, 161-165.	4.1	117

#	Article	IF	CITATIONS
415	Use of contraceptive methods among women treated for bipolar disorder. Archives of Women's Mental Health, 2009, 12, 183-185.	2.6	29
416	Sleep in bipolar patients. Sleep and Breathing, 2009, 13, 169-173.	1.7	43
417	The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers. Acta Neuropsychiatrica, 2009, 21, 272-274.	2.1	29
418	Birthâ€cohort and dual diagnosis effects on ageâ€atâ€onset in Brazilian patients with bipolar I disorder. Acta Psychiatrica Scandinavica, 2009, 120, 492-495.	4.5	17
419	Brainâ€derived neurotrophic factor in bipolar disorder: beyond <i>trait</i> and <i>state</i> : comment on †Decreased levels of serum brainâ€derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders'. Bipolar Disorders, 2009, 11, 221-222.	1.9	11
420	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disorders, 2009, 11, 225-255.	1.9	545
421	Clinical predictors of functional outcome of bipolar patients in remission. Bipolar Disorders, 2009, 11, 401-409.	1.9	156
422	The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disorders, 2009, 11, 453-473.	1.9	401
423	Cognitive function and serum levels of brainâ€derived neurotrophic factor in patients with bipolar disorder. Bipolar Disorders, 2009, 11, 663-671.	1.9	80
424	Problems with singleâ€factor solutions in factor analyses of lowâ€end scores. Bipolar Disorders, 2009, 11, 900-900.	1.9	1
425	Validity of a Short Functioning Test (FAST) in Brazilian Outpatients with Bipolar Disorder. Value in Health, 2009, 12, 624-627.	0.3	65
426	Marcadores de estrés oxidativo en el trastorno bipolar: un metaanálisis. Psiquiatria Biologica, 2009, 16, 60-69.	0.1	0
427	Abnormalities in serum chemokine levels in euthymic patients with Bipolar Disorder. Brain, Behavior, and Immunity, 2009, 23, 1079-1082.	4.1	119
428	Psychometric properties of the Parkinson's Disease Sleep Scale – Brazilian version. Parkinsonism and Related Disorders, 2009, 15, 495-499.	2.2	29
429	Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 450-455.	4.8	214
430	Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 1425-1430.	4.8	109
431	The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 1366-1371.	4.8	139
432	Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neuroscience Letters, 2009, 452, 111-113.	2.1	117

#	Article	IF	CITATIONS
433	Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): A pilot study in drug resistant depressed patients. Neuroscience Letters, 2009, 453, 195-198.	2.1	72
434	Striatum brain-derived neurotrophic factor levels are decreased in dystrophin-deficient mice. Neuroscience Letters, 2009, 459, 66-68.	2.1	9
435	Clinical implications of a staging model for bipolar disorders. Expert Review of Neurotherapeutics, 2009, 9, 957-966.	2.8	214
436	Advances in the Pathophysiology of Episode-Related Cognitive Impairment in Bipolar Disorder. European Psychiatry, 2009, 24, .	0.2	0
437	Increased Serum Neurotrophin-4/5 Levels in Bipolar Disorder. European Psychiatry, 2009, 24, .	0.2	1
438	Development and use of a Biological Rhythm Interview. European Psychiatry, 2009, 24, .	0.2	1
439	Waist Circumference as a Simple and Meaningful Means to Assess Insulin Resistance Among Outpatients with Bipolar Disorder. European Psychiatry, 2009, 24, .	0.2	0
440	Clinical Factors as Predictors on Functional Impairment in Bipolar Disorder. European Psychiatry, 2009, 24, .	0.2	0
441	Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. International Journal of Neuropsychopharmacology, 2009, 12, 447.	2.1	343
442	Lower rates of comorbidities in euthymic bipolar patients. World Journal of Biological Psychiatry, 2009, 10, 474-479.	2.6	15
443	Epidemiology and Management of Anxiety in Patients with Bipolar Disorder. CNS Drugs, 2009, 23, 953-964.	5.9	30
444	Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. Journal of Affective Disorders, 2009, 116, 214-217.	4.1	376
445	Accelerated age-related decrease in brain-derived neurotrophic factor levels in bipolar disorder. International Journal of Neuropsychopharmacology, 2009, 12, 137.	2.1	46
446	Reduced NGF Secretion by HT-29 Human Colon Cancer Cells Treated with a GRPR Antagonist. Protein and Peptide Letters, 2009, 16, 650-652.	0.9	8
447	Brazil launches an innovative program to develop the National Institutes for Science and Technology (INCTs): the INCT for Translational Medicine. Revista Brasileira De Psiquiatria, 2009, 31, 197-199.	1.7	4
448	3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. Journal of Psychiatry and Neuroscience, 2009, 34, 263-71.	2.4	140
449	Lack of effect of antipsychotics on BNDF and NGF levels in hippocampus of Wistar rats. Metabolic Brain Disease, 2008, 23, 213-219.	2.9	15
450	Intense Exercise Induces Mitochondrial Dysfunction in Mice Brain. Neurochemical Research, 2008, 33, 51-58.	3.3	43

#	Article	IF	CITATIONS
451	Downhill training upregulates mice hippocampal and striatal brain-derived neurotrophic factor levels. Journal of Neural Transmission, 2008, 115, 1251-1255.	2.8	55
452	Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 300-304.	3.2	109
453	The impact of co-morbid alcohol use disorder in bipolar patients. Alcohol, 2008, 42, 451-457.	1.7	82
454	Allostatic load in bipolar disorder: Implications for pathophysiology and treatment. Neuroscience and Biobehavioral Reviews, 2008, 32, 675-692.	6.1	416
455	Oxidative stress may be a common mechanism linking major depression and osteoporosis. Acta Neuropsychiatrica, 2008, 20, 112-116.	2.1	23
456	When illness does not get better: do we need a palliative psychiatry?. Acta Neuropsychiatrica, 2008, 20, 165-166.	2.1	10
457	Functional impairment and previous suicide attempts in bipolar disorder. Acta Neuropsychiatrica, 2008, 20, 300-306.	2.1	14
458	Chronic Administration of Ketamine Elicits Antidepressantâ€Like Effects in Rats without Affecting Hippocampal Brainâ€Đerived Neurotrophic Factor Protein Levels. Basic and Clinical Pharmacology and Toxicology, 2008, 103, 502-506.	2.5	101
459	Predominant polarity in bipolar disorder: Diagnostic implications. Journal of Affective Disorders, 2008, 107, 45-51.	4.1	98
460	Insight, quality of life and cognitive functioning in euthymic patients with bipolar disorder. Journal of Affective Disorders, 2008, 110, 75-83.	4.1	82
461	Oxidative stress markers in bipolar disorder: A meta-analysis. Journal of Affective Disorders, 2008, 111, 135-144.	4.1	442
462	Effects of lithium and valproate on serum and hippocampal neurotrophin-3 levels in an animal model of mania. Journal of Psychiatric Research, 2008, 42, 416-421.	3.1	51
463	Brain creatine kinase activity in an animal model of mania. Life Sciences, 2008, 82, 424-429.	4.3	52
464	Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. Neuroscience Letters, 2008, 433, 270-273.	2.1	34
465	Decreased serum neurotrophin 3 in chronically medicated schizophrenic males. Neuroscience Letters, 2008, 440, 197-201.	2.1	22
466	Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 140-144.	4.8	377
467	TNF-α as a molecular target in bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1355-1361.	4.8	140
468	Effect of N-acetylcysteine and/or deferoxamine on oxidative stress and hyperactivity in an animal model of mania. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1064-1068.	4.8	41

#	Article	IF	CITATIONS
469	Serum levels of brain-derived neurotrophic factor in schizophrenia on a hypocaloric diet. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1595-1598.	4.8	32
470	Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1677-1681.	4.8	188
471	Peripheral nucleotide hydrolysis in rats submitted to a model of electroconvulsive therapy. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1829-1833.	4.8	13
472	Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Review of Neurotherapeutics, 2008, 8, 1101-1113.	2.8	146
473	Functional Impairment in Patients with Remitted Bipolar Disorder. Psychotherapy and Psychosomatics, 2008, 77, 390-392.	8.8	68
474	Cognitive Performance and Quality of Life in Bipolar Disorder. Canadian Journal of Psychiatry, 2008, 53, 517-524.	1.9	76
475	Emotional memory in bipolar disorder. British Journal of Psychiatry, 2008, 192, 458-463.	2.8	26
476	Chronic Mild Stress Paradigm Reduces Sweet Food Intake in Rats without Affecting Brain Derived Neurotrophic Factor Protein Levels. Current Neurovascular Research, 2008, 5, 207-213.	1.1	45
477	Serum levels of brain-derived neurotrophic factor and thiobarbituric acid reactive substances in chronically medicated schizophrenic patients: a positive correlation. Revista Brasileira De Psiquiatria, 2008, 30, 337-340.	1.7	28
478	Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes. Revista Brasileira De Psiquiatria, 2008, 30, 243-245.	1.7	129
479	Cognitive impairment in a Brazilian sample of patients with bipolar disorder. Revista Brasileira De Psiquiatria, 2008, 30, 209-214.	1.7	9
480	A Double-Blind, Randomized, Placebo-Controlled 4-Week Study on the Efficacy and Safety of the Purinergic Agents Allopurinol and Dipyridamole Adjunctive to Lithium in Acute Bipolar Mania. Journal of Clinical Psychiatry, 2008, 69, 1237-1245.	2.2	111
481	Effects of mood stabilizers on DNA damage in an animal model of mania. Journal of Psychiatry and Neuroscience, 2008, 33, 516-24.	2.4	62
482	Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clinical Practice and Epidemiology in Mental Health, 2007, 3, 5.	1.2	605
483	Anxiety Comorbidity and Quality of Life in Bipolar Disorder Patients. Canadian Journal of Psychiatry, 2007, 52, 175-181.	1.9	67
484	Sensitization and cross-sensitization after chronic treatment with methylphenidate in adolescent Wistar rats. Behavioural Pharmacology, 2007, 18, 205-212.	1.7	45
485	The role of hippocampus in the pathophysiology of bipolar disorder. Behavioural Pharmacology, 2007, 18, 419-430.	1.7	149
486	Late-Onset Neuroleptic Malignant Syndrome in a Patient Using Olanzapine. Journal of Clinical Psychopharmacology, 2007, 27, 303-304.	1.4	6

#	Article	IF	CITATIONS
487	DNA damage in bipolar disorder. Psychiatry Research, 2007, 153, 27-32.	3.3	145
488	Manic symptoms and quality of life in bipolar disorder. Psychiatry Research, 2007, 153, 33-38.	3.3	35
489	A gastrin-releasing peptide receptor antagonist blocks d-amphetamine-induced hyperlocomotion and increases hippocampal NGF and BDNF levels in rats. Peptides, 2007, 28, 1447-1452.	2.4	18
490	Increased oxidative stress and DNA damage in bipolar disorder: A twin-case report. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 283-285.	4.8	104
491	Correlation between drug treatment adherence and lithium treatment attitudes and knowledge by bipolar patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 217-224.	4.8	80
492	Effects of lithium and valproate on hippocampus citrate synthase activity in an animal model of mania. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 887-891.	4.8	43
493	DNA damage in rats after treatment with methylphenidate. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1282-1288.	4.8	64
494	Serum neurotrophin-3 is increased during manic and depressive episodes in bipolar disorder. Neuroscience Letters, 2007, 415, 87-89.	2.1	58
495	Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neuroscience Letters, 2007, 420, 45-48.	2.1	135
496	Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: A possible role for lithium antioxidant effects. Neuroscience Letters, 2007, 421, 33-36.	2.1	281
497	Mitochondrial IV complex and brain neurothrophic derived factor responses of mice brain cortex after downhill training. Neuroscience Letters, 2007, 426, 171-174.	2.1	24
498	Decreased Plasma Brain Derived Neurotrophic Factor Levels in Unmedicated Bipolar Patients During Manic Episode. Biological Psychiatry, 2007, 61, 142-144.	1.3	187
499	Val66met polymorphism and serum brain-derived neurotrophic factor levels in bipolar disorder. Molecular Psychiatry, 2007, 12, 230-231.	7.9	51
500	Abnormal cellular energy and phospholipid metabolism in the left dorsolateral prefrontal cortex of medication-free individuals with bipolar disorder: an in vivo1H MRS study. Bipolar Disorders, 2007, 9, 119-127.	1.9	107
501	Traumatic life events in bipolar disorder: impact on BDNF levels and psychopathology. Bipolar Disorders, 2007, 9, 128-135.	1.9	128
502	Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatrica Scandinavica, 2007, 116, 41-49.	4.5	317
503	Mismatch between self-reported quality of life and functional assessment in acute mania: A matter of unawareness of illness?. Journal of Affective Disorders, 2007, 103, 247-252.	4.1	49
504	Serum S100B and antioxidant enzymes in bipolar patients. Journal of Psychiatric Research, 2007, 41, 523-529.	3.1	269

#	Article	IF	CITATIONS
505	Basic Fibroblast Growth Factor Prevents the Memory Impairment Induced by Gastrin-Releasing Peptide Receptor Antagonism in Area CA1 of the Rat Hippocampus. Neurochemical Research, 2007, 32, 1381-1386.	3.3	8
506	Oxidative Stress and S100B Protein in Cirrhotic Children. Neurochemical Research, 2007, 32, 1600-1603.	3.3	7
507	Immunoassay for glial fibrillary acidic protein: Antigen recognition is affected by its phosphorylation state. Journal of Neuroscience Methods, 2007, 162, 282-286.	2.5	65
508	Polypharmacy and suicide attempts in bipolar disorder. Revista Brasileira De Psiquiatria, 2007, 29, 35-38.	1.7	14
509	Azapirones for generalized anxiety disorder. The Cochrane Library, 2006, , CD006115.	2.8	75
510	Acute and chronic electroconvulsive shock in rats: Effects on peripheral markers of neuronal injury and glial activity. Life Sciences, 2006, 78, 3013-3017.	4.3	34
511	Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sciences, 2006, 79, 281-286.	4.3	211
512	Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neuroscience Letters, 2006, 398, 215-219.	2.1	343
513	Increased serum glial cell line-derived neurotrophic factor immunocontent during manic and depressive episodes in individuals with bipolar disorder. Neuroscience Letters, 2006, 407, 146-150.	2.1	84
514	Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: A study of patients treated with haloperidol or clozapine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 512-515.	4.8	101
515	Glial fibrillary acidic protein expression after electroconvulsive shocks in rat brain. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 663-667.	4.8	6
516	Evidence of astrogliosis in rat hippocampus after d-amphetamine exposure. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 1231-1234.	4.8	15
517	Bipolar depression: the importance of being on remission. Revista Brasileira De Psiquiatria, 2006, 28, 93-96.	1.7	27
518	Lithium increases nerve growth factor levels in the rat hippocampus in an animal model of mania. Behavioural Pharmacology, 2006, 17, 311-318.	1.7	41
519	Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disorders, 2006, 8, 275-280.	1.9	95
520	Changes in Antioxidant Defense Enzymes after d-amphetamine Exposure: Implications as an Animal Model of Mania. Neurochemical Research, 2006, 31, 699-703.	3.3	90
521	Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure. Brain Research, 2006, 1097, 224-229.	2.2	75
522	Adaptation and validation of the Portuguese version of the Lithium Knowledge Test (LKT) of bipolar patients treated with lithium: cross-over study. Clinical Practice and Epidemiology in Mental Health, 2006, 2, 34.	1.2	3

#	Article	IF	CITATIONS
523	Validation of the Portuguese version of the Lithium Attitudes Questionnaire (LAQ) in bipolar patients treated with lithium: cross-over study. Clinical Practice and Epidemiology in Mental Health, 2006, 2, 32.	1.2	5
524	An Open Trial of Adjunctive Escitalopram in Bipolar Depression. Journal of Clinical Psychiatry, 2006, 67, 81-86.	2.2	16
525	Bipolar disorder: building the path of return to the ideas of Kraepelin. Revista Brasileira De Psiquiatria, 2006, 28, 82-82.	1.7	0
526	Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. Journal of Psychiatry and Neuroscience, 2006, 31, 326-32.	2.4	176
527	CANMAT guidelines for bipolar disorder: a commentary from South America. Bipolar Disorders, 2005, 7, 87-88.	1.9	5
528	Clinical impact of late diagnose of bipolar disorder. Journal of Affective Disorders, 2005, 86, 313-316.	4.1	42
529	A proton magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in acute mania. Human Psychopharmacology, 2005, 20, 133-139.	1.5	24
530	Changes in S100B cerebrospinal fluid levels of rats subjected to predator stress. Brain Research, 2004, 1028, 213-218.	2.2	27
531	Perspectives for the development of animal models of bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 209-224.	4.8	140
532	Increased cerebrospinal fluid levels of S100B protein in rat model of mania induced by ouabain. Life Sciences, 2004, 76, 805-811.	4.3	30
533	Seasonal distribution and demographical characteristics of carpal tunnel syndrome in 1039 patients. Arquivos De Neuro-Psiquiatria, 2004, 62, 596-599.	0.8	7
534	The acute effect of methylphenidate on cerebral blood flow in boys with attention-deficit/hyperactivity disorder. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 423-426.	6.4	54
535	Differential involvement of hippocampal and amygdalar NMDA receptors in contextual and aversive aspects of inhibitory avoidance memory in rats. Brain Research, 2003, 975, 207-213.	2.2	67
536	Differential effects of emotional arousal in short- and long-term memory in healthy adults. Neurobiology of Learning and Memory, 2003, 79, 132-135.	1.9	76
537	Cognitive-Behavioral Group Therapy in Obsessive-Compulsive Disorder: A Randomized Clinical Trial. Psychotherapy and Psychosomatics, 2003, 72, 211-216.	8.8	133
538	Effects of Gabapentin on Anxiety Induced by Simulated Public Speaking. Journal of Psychopharmacology, 2003, 17, 184-188.	4.0	40
539	Dose-related effects of propericiazine in rats. Brazilian Journal of Medical and Biological Research, 2003, 36, 227-231.	1.5	8
540	An Open Trial of Reboxetine in HIV-Seropositive Outpatients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2003, 64, 421-424.	2.2	16

#	Article	IF	CITATIONS
541	Behavioural effects of acute phenylalanine and tyrosine depletion in healthy male volunteers. Journal of Psychopharmacology, 2002, 16, 51-55.	4.0	27
542	Interaction between midazolam-induced anterograde amnesia and memory enhancement by treatments given immediately after training on an inhibitory avoidance task in rats. Behavioural Pharmacology, 2002, 13, 319-322.	1.7	7
543	Elevated serum S100B protein in drug-free bipolar patients during first manic episode: a pilot study. European Neuropsychopharmacology, 2002, 12, 269-272.	0.7	61
544	Purinergic dysfunction in mania: an integrative model. Medical Hypotheses, 2002, 58, 297-304.	1.5	79
545	Cognitive-behavioral group therapy in obsessive-compulsive disorder: a clinical trial. Revista Brasileira De Psiquiatria, 2002, 24, 113-120.	1.7	26
546	The serum S100B concentration is age dependent. Clinical Chemistry, 2002, 48, 950-2.	3.2	38
547	Mirtazapine versus fluoxetine in the treatment of panic disorder. Brazilian Journal of Medical and Biological Research, 2001, 34, 1303-1307.	1.5	72
548	Mania Associated with an Energy Drink: The Possible Role of Caffeine, Taurine, and Inositol. Canadian Journal of Psychiatry, 2001, 46, 454-455.	1.9	48
549	Comparative pharmacological study of hydroethanol extracts ofPassiflora alata andPassiflora edulis leaves. Phytotherapy Research, 2001, 15, 162-164.	5.8	85
550	USE AND MISUSE OF BENZODIAZEPINES IN BRAZIL: A REVIEW. Substance Use and Misuse, 2001, 36, 1053-1069.	1.4	32
551	Therapeutic Efficacy of Allopurinol in Mania Associated With Hyperuricemia. Journal of Clinical Psychopharmacology, 2001, 21, 621-622.	1.4	44
552	The anticonvulsant compound gabapentin possesses anxiolytic but not amnesic effects in rats. Behavioural Pharmacology, 2000, 11, 169-173.	1.7	40
553	Evoked Potentials for the Evaluation of Latent Hepatic Encephalopathy in Pediatric Liver Transplant Candidates. Journal of Pediatric Gastroenterology and Nutrition, 2000, 31, 371-376.	1.8	4
554	Behavioural effects of acute tryptophan depletion in healthy male volunteers. Journal of Psychopharmacology, 2000, 14, 157-163.	4.0	32
555	Clozapine-induced neuroleptic malignant syndrome: an interaction between dopaminergic and purinergic systems?. Journal of Psychopharmacology, 1999, 13, 318-319.	4.0	14
556	Brain uptake of iomazenil in cirrhotic patients: a single photon emission tomography study. Journal of Psychopharmacology, 1999, 13, 219-225.	4.0	1
557	Flumazenil and hepatic encephalopathy. Hepatology, 1999, 29, 1338a-1339.	7.3	0
558	Pharmacokinetics of radiotracers in human plasma during positron emission tomography. , 1999, 34, 124-134.		32

#	Article	IF	CITATIONS
559	Drugs acting at the glycine site on the NMDA receptor as cognitive enhancers in patients with Alzheimer's disease. Neurology, 1998, 50, 1195-1195.	1.1	2
560	Cognitive impairments of alcoholic cirrhotic patients: correlation with endogenous benzodiazepine receptor ligands and increased affinity of platelet receptors Journal of Neurology, Neurosurgery and Psychiatry, 1996, 60, 676-680.	1.9	10
561	Differential effects of flumazenil in alcoholic and nonalcoholic cirrhotic patients. Psychopharmacology, 1995, 120, 220-226.	3.1	17
562	Central benzodiazepine receptor imaging and quantitation with single photon emission computerised tomography: SPECT. Journal of Psychopharmacology, 1995, 9, 369-380.	4.0	4
563	Flumazenil has an anxiolytic effect in simulated stress. Psychopharmacology, 1994, 114, 187-189.	3.1	58
564	Observing Countertransference in Brief Dynamic Psychotherapy. Psychotherapy and Psychosomatics, 1991, 56, 174-181.	8.8	11
565	Memory modulation by post-training intraperitoneal, but not intracerebroventricular, administration of ACTH or epinephrine. Behavioral and Neural Biology, 1983, 39, 277-283.	2.2	24
566	Adjunctive antioxidants for bipolar disorder. The Cochrane Library, 0, , .	2.8	0
567	Oxidative stress and neuronal resilience – implications for the pathophysiology of bipolar disorder. , 0, , 61-69.		0
568	Longitudinal course of bipolar disorder. Revista Debates Em Psiquiatria, 0, Ano 6, 6-8.	0.3	0
569	Lifestyle Behaviors, Depression, and Anxiety Among Individuals Living in Canada During the COVID-19 Pandemic. American Journal of Lifestyle Medicine, 0, , 155982762211020.	1.9	Ο

33